This pie chart shows research & development funding for STI vaccines and diagnostics by topic.
Excerpted from STIs: A Review of the 2022 Vaccine and Diagnostic R&D Pipeline and Investments, the full report is available at stiwatch.org/resource-tracking.
This pie chart shows research & development funding for STI vaccines and diagnostics by sector — public and philanthropic.
Excerpted from STIs: A Review of the 2022 Vaccine and Diagnostic R&D Pipeline and Investments, the full report is available at stiwatch.org/resource-tracking.
This report examines disbursements by the U.S. NIH and the Bill & Melinda Gates Foundation and is one of few reports to track funding trends in vaccine and diagnostics R&D, and pipeline investments for some of the most common STIs, including chlamydia, genital herpes, gonorrhea, hepatitis B, human papillomavirus (HPV), syphilis, and trichomoniasis.
Join us in telling Congress to reject cuts and #SaveHIVFunding by sending letters to your Congressional representatives.
In the year ahead, staking out a course that will advance the HIV response and global health equity faces serious headwinds.
The Coalition to Accelerate Access to Long-Acting PrEP is an initiative that brings together leading donors, agencies, and advocates to ensure an accelerated, equitable, sustainable and collaborative approach to making longer-acting PrEP options accessible as quickly and as equitably as possible. The Coalition is convened by Unitaid, WHO, UNAIDS, Global Fund and PEPFAR, with AVAC as the Secretariat.
The Coalition to Accelerate Access to Long-Acting PrEP brings together leading donors, agencies, and advocates aimed at a practical goal: jointly develop strategies and take coordinated action to identify and overcome access challenges to just-approved and future PrEP options. AVAC serves as the Secretariat.
AVAC is thrilled to see the launch of injectable cabotegravir for PrEP (injectable CAB) in Zambia—the first program outside of the US to do so. And the Desmond Tutu Health Foundation in South Africa recently announced “the first jab” of injectable CAB administered in its FASTPrEP study.
AVAC and REACH for the Cure hosted a webinar to discuss how the environment may impact HIV cure strategies. During this webinar, both organizations explored how clades, co-infections, early treatment, and other factors can help inform existing approaches to HIV cure research. Dr. Adam Ward of Weill Cornell Medicine shared the latest data followed by an informal conversation.
Download the application here or click the link on the right of this page.
The Advocacy Navigator is an AVAC initiative combining training and mentorship to young and emerging advocates in the field of HIV prevention advocacy. Mentors will serve as advisors to the Navigators, supporting them as they go through their coursework and while they design and implement their Community Advocacy Project. More information at www.avac.org/navigator.